항우울제의 사용과 체중 = Usage of Antidepressants and Weight

다국어 초록 (Multilingual Abstract)

Depressive disorder is a very common disease, clinical manifestations vary, and the mechanism is not clear. Therefore, a pharmacotherapy is very important to achieve sufficient therapeutic effect, but the choice of drug is not easy due to the occurrence of side effects of treatment and confusion with clinical features. It is easy to overlook the side effects of weight gain with antidepressants compared with antipsychotics, but they are frequently observed in clinical settings. The first-generation antidepressants have higher weight gains than selective serotonin reuptake inhibitors. Serotonin norepinephrine reuptake inhibitors are observed to have less weight gain, and dopamine norepinephrine reuptake inhibitors have weight loss effect due to decreased appetite. Mirtazapine, an atypical antidepressant, has a strong histamine H1 blockade, and gains weight gain from short-term use. The effects of desvenlafaxine, vortioxetine, and agomelatin on weight, which have recently been increasing in use, have not been largely identified. For better compliance, studies on weight gain due to the use of antidepressants are needed.

참고문헌 (Reference)

1 조맹제, "한국 주요정신장애의 유병률 및 관련요인：2006 전국정신질환역학조사" 대한신경정신의학회 48 (48): 143-152, 2009

2 송후림, "신경염증과 정신질환" 대한생물정신의학회 23 (23): 12-17, 2016

3 정희정, "새로운 우울증 치료 약물" 대한생물정신의학회 23 (23): 1-11, 2016

4 Berken GH, "Weight gain. A side-effect of tricyclic antidepressants" 7 : 133-138, 1984

5 Garland EJ, "Weight gain with antidepressants and lithium" 8 : 323-330, 1988

6 Benazzi F, "Weight gain in depression remitted with antidepressants : pharmacological or recovery effect" 67 : 271-274, 1998

7 Fava M, "Weight gain and antidepressants" 61 (61): 37-41, 2000

8 Goodnick PJ, "Weight change during mirtazapine therapy" 3 : 103-108, 1998

9 Nierenberg AA, "Treatment-resistant bipolar depression : a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone" 163 : 210-216, 2006

10 Papakostas GI, "Towards new mechanisms : an update on therapeutics for treatment-resistant major depressive disorder" 20 : 1142-1150, 2015

11 Cho SJ, "The relationship between visceral adiposity and depressive symptoms in the general Korean population" 244 : 54-59, 2019

12 Andrade L, "The epidemiology of major depressive episodes : results from the International Consortium of Psychiatric Epidemiology(ICPE)Surveys" 12 : 3-21, 2003

13 Moon CA, "The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice" 45 : 259-262, 1991

14 Levitt AJ, "The effect of desipramine on body weight in depression" 48 : 27-28, 1987

15 Jieun Lee, "The Tolerability of Mirtazapine Augmentation in Schizophrenic Patients Treated with Risperidone: A Preliminary Randomized Placebo-controlled Trial" 대한정신약물학회 9 (9): 73-77, 2011

16 Bahk WM, "Textbook of depressive disorders" Sigma press 2012

17 Korean Neuropsychiatric Association, "Textbook of Neuropsychiatry" iMiS Company 2017

18 Caffey EM Jr, "Side effects and laboratory findings in a study of anti-depressant drugs" 23 : 444-449, 1962

19 Aberg-Wistedt A, "Sertraline versus paroxetine in major depression : clinical outcome after six months of continuous therapy" 20 : 645-652, 2000

20 Alam MY, "Safety, tolerability, and efficacy of vortioxetine(Lu AA21004)in major depressive disorder : results of an open-label, flexible-dose, 52-week extension study" 29 : 36-44, 2014

21 Shi Z, "SSRI antidepressant use potentiates weight gain in the context of unhealthy lifestyles : results from a 4-year Australian follow-up study" 7 : e016224-, 2017

22 Benjamin S, "Review of the use of mirtazapine in the treatment of depression" 12 : 1623-1632, 2011

23 Robins LN, "Psychiatric Disorders in America: The Epidemiologic Catchment Area Study" The Free Press 1991

24 Bouwer CD, "Phasic craving for carbohydrate observed with citalopram" 11 : 273-278, 1996

25 Silverstone PH, "Once-daily venlafaxine extended release(XR)compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group" 60 : 22-28, 1999

26 Smith WT, "Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder" 26 : 191-196, 1990

27 Montgomery SA, "Mirtazapine versus amitriptyline in the long-term treatment of depression : a double-blind placebo-controlled study" 13 : 63-73, 1998

28 Cho SJ, "Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial" 35 : 208-211, 2011

29 Britton DR, "Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty" 31 : 363-367, 1982

30 Leonard BE, "Impact of inflammation on neurotransmitter changes in major depression : an insight into the action of antidepressants" 48 : 261-267, 2014

31 Fernstrom MH, "Imipramine treatment and preference for sweets" 10 : 149-155, 1988

32 Frank E, "Imipramine and weight gain during the treatment of recurrent depression" 20 : 165-172, 1990

33 Frank E, "Imipramine and weight gain during the long-term treatment of recurrent depression" 26 : 65-72, 1992

34 Assari S, "Gender and Ethnic Differences in the association between obesity and depression among black adolescents" 2 : 481-493, 2015

35 Fava M, "Fluoxetine versus sertraline and paroxetine in major depressive disorder : changes in weight with long-term treatment" 61 : 863-867, 2000

36 Sussman N, "Effects of psychotropic drugs on weight" 29 : 580-594, 1999

37 Harto-Truax N, "Effects of bupropion on body weight" 44 : 183-186, 1983

38 Pijl H, "Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity" 15 : 237-242, 1991

39 Levine AS, "Effect of centrally administered corticotropin releasing factor(CRF)on multiple feeding paradigms" 22 : 337-339, 1983

40 Feiger AD, "Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression" 14 : 19-28, 1999

41 Hoffman BJ, "Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain" 247 : 453-462, 1989

42 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" American Psychaitric Association 2013

43 Fava M, "Diagnosis and definition of treatment-resistant depression" 53 : 649-659, 2003

44 Tourian KA, "Desvenlafaxine and weight change in major depressive disorder" 12 : e1-e8, 2010

45 Fernstrom MH, "Depression, antidepressants, and body weight change" 575 : 31-39, 1989

46 Grundy SM, "Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition" 24 : e13-e18, 2004

47 Wright DE, "Comparative localization of serotonin1A, 1C, and 2 receptor subtype mRNAs in rat brain" 351 : 357-373, 1995

48 Michelson D, "Changes in weight during a 1-year trial of fluoxetine" 156 : 1170-1176, 1999

49 Pan A, "Bidirectional association between depression and metabolic syndrome : a systematic review and meta-analysis of epidemiological studies" 35 : 1171-1180, 2012

50 Fava M, "Augmentation and combination strategies in treatment-resistant depression" 62 (62): 4-11, 2001

51 Fernstrom MH, "Antidepressant-induced weight gain : a comparison study of four medications" 26 : 265-271, 1988

52 Gafoor R, "Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study" 361 : k1951-, 2018

53 Weilburg JB, "An overview of SSRI and SNRI therapies for depression" 13 : 25-33, 2004

54 Guaiana G, "Agomelatine versus other antidepressive agents for major depression" CD008851-, 2013

55 de Jonghe F, "A randomized, doubleblind study of fluoxetine and maprotiline in the treatment of major depression" 24 : 62-67, 1991

56 Croft H, "A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline" 21 : 643-658, 1999

57 Hillhouse TM, "A brief history of the development of antidepressant drugs : from monoamines to glutamate" 23 : 1-21, 2015